Stocktoria
CorMedix Inc. CRMD
CorMedix Inc. (CRMD) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $311.7M at a 52.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.233 |
| Retained earnings / assets | -0.214 |
| EBIT / assets | 0.182 |
| Equity / liabilities | 0.963 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CRMD | CorMedix Inc. | 5/9 | 3.07 | 3.8 | +617% |
| EOLS | Evolus, Inc. | 2/9 | -8.65 | — | +11.6% |
| IRWD | IRONWOOD PHARMACEUTICALS INC | 4/9 | -11.97 | 28.3 | -15.7% |
| RIGL | RIGEL PHARMACEUTICALS INC | 5/9 | 0.31 | 2 | +64.1% |
| XERS | Xeris Biopharma Holdings, Inc. | 7/9 | -2.99 | — | +43.7% |
| AUPH | Aurinia Pharmaceuticals Inc. | 5/9 | 5.18 | 7.7 | +20.4% |
| MNKD | MANNKIND CORP | 3/9 | -11.89 | 218.2 | +22.2% |
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
FAQ
Is CRMD financially healthy?
CorMedix Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does CRMD pay a dividend?
No, CorMedix Inc. does not currently pay a dividend.
How profitable is CRMD?
In FY2025, CorMedix Inc. had a net margin of 52.3% and a return on equity of 40.2%.
What is CRMD's P/E ratio?
CorMedix Inc.'s trailing price-to-earnings (P/E) ratio is about 3.8×, based on its latest annual earnings.
What is the analyst price target for CRMD?
The average Wall-Street price target for CorMedix Inc. is $15.20, about 114.1% above the recent price, from 5 analysts (consensus: buy).
Is CRMD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CorMedix Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 3.8×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.